<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955186</url>
  </required_header>
  <id_info>
    <org_study_id>1601017043</org_study_id>
    <nct_id>NCT02955186</nct_id>
  </id_info>
  <brief_title>Saracatinib and Alcohol Drinking</brief_title>
  <official_title>Fyn Kinase Inhibitors and Alcohol Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of the study medication,
      saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory
      setting in which participants are given an initial drink of alcohol followed by the choice to
      drink up to 12 more drinks over a three-hour period. The investigators hypothesize that
      saracatinib will reduce craving and number of drinks consumed prior to and after exposure to
      the initial drink of alcohol and during the three hour drinking period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Drinks Consumed on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Number of drinks consumed on Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline adjusted Craving (YCS)</measure>
    <time_frame>Day 8</time_frame>
    <description>Craving for alcohol based on Yale Craving Scale, scores ranging from 0-112 mm on a visual analog scale, with higher measurements indicating higher craving. The baseline-adjusted craving is change score from baseline at Day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stimulation and Sedation Responses to Alcohol (BAES)</measure>
    <time_frame>Day 8</time_frame>
    <description>Biphasic Alcohol Effects Scale scores will be used to assess stimulation and sedation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>125 mg saracatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take 125 mg of saracatinib daily for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo daily for 8 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saracatinib</intervention_name>
    <description>Saracatinib 125 mg once per day for 8 days</description>
    <arm_group_label>125 mg saracatinib</arm_group_label>
    <other_name>AZD0530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo once per day for 8 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 21-50

          -  Able to read English at 6th grade level or higher and to complete study evaluations

          -  Regular alcohol drinker

        Exclusion Criteria:

          -  Individuals who are seeking alcohol treatment

          -  Medical conditions that would contraindicate the use of saracatinib

          -  Regular use of other substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dana Cavallo, PhD</last_name>
    <phone>203-974-7607</phone>
    <email>dana.cavallo@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Franco, BA</last_name>
    <phone>203-974-7679</phone>
    <email>nicholas.franco@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CMHC, Substance Abuse Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana A Cavallo, Ph.D.</last_name>
      <phone>203-974-7607</phone>
      <email>dana.cavallo@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Suchitra Krishnan-Sarin</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

